

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 - 24. (Canceled)

25. (Previously presented) A method for selecting determining treatments for a cancer patient, comprising:

collecting genomic DNA from the patient;

amplifying the HLA DQB1* (Major histocompatibility complex, class II, DQ beta 1)

gene from the genomic DNA using an automated PCR thermal sequencer;

determining what identifying the amino acids are encoded by at positions 57 and 67 of the amino acid sequence encoded by the HLA DQB1* (Major histocompatibility complex, class II, DQ beta 1) gene of the patient; and

determining anti-cancer immunotherapy after cancer resection to have a statistically significant probability of prolonging the cancer patient's survival, when by determining that Asp is encoded at position 57 and Val is encoded at position 67 of the amino acid sequence encoded by the HLA DQB1* (Major histocompatibility complex, class II, DQ beta 1) gene; and

selecting anti-cancer immunotherapy after cancer resection, as a treatment for the patient;

wherein the cancer of the patient comprises is stomach cancer.

26-28. Canceled.